Crescent Biopharma Inc (CBIO) Stock Price, Quote & News

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 460 5595

Website: crescentbiopharma.com

Address:

300 Fifth Avenue, Waltham, United States

NVDAMillionaire May. 13 at 6:04 PM

$CBIO Excellent article that nails exactly where CBIO stands right now. So if you want to update your CBIO knowledge or get acquainted with CBIO, this is a must read. https://everyticker.com/quote/CBIO/analysis/crescent-biopharma-s-189m-clinical-reset-three-shots-at-a-13b-valuation-nasdaq-cbio

0 · Reply

MorenitaScorp May. 5 at 2:18 PM

$CBIO ⌚️

0 · Reply

PenkeInvesting May. 4 at 4:20 PM

Fundamental analysis of $CBIO (CRESCENT BIOPHARMA, INC.) based on financial data and reported results. #CBIO

0 · Reply

OfficialStocktwitsUser May. 2 at 12:33 AM

$CBIO RSI: 50.18, MACD: 1.7787 Vol: 2.90, MA20: 21.33, MA50: 16.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

lyonsa14 May. 1 at 5:56 PM

$CBIO Looks like it’s falling in sympathy with Summit Therapeutics. https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble

0 · Reply

ProfProfit May. 1 at 3:44 PM

$CBIO why the 30% drop today?

0 · Reply

stockanalysis_ May. 1 at 1:49 PM

Losers Today: $CREG $SKBL $CBIO $SDOT $BAFN Download this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

SuperGreenToday Apr. 28 at 8:54 AM

$CBIO

0 · Reply

Estimize Apr. 21 at 11:03 PM

Wall St is expecting -0.88 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c

0 · Reply

Jt11111 Apr. 21 at 7:36 PM

$CBIO something gotta be cooking

0 · Reply

Crescent Biopharma Announces Grants of Inducement Awards

May 6, 2026, 7:30 AM EDT - 7 days ago

Crescent Biopharma to Present at May Investor Conferences

2026-04-29T21:25:20.000Z - 13 days ago

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Apr 29, 2026, 4:15 PM EDT - 14 days ago

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-04-08T20:50:50.000Z - 4 weeks ago

Crescent Biopharma management to meet with Cantor Fitzgerald

Mar 11, 2026, 8:40 AM EDT - 2 months ago

Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 2 months ago

Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:44:56.000Z - 2 months ago

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

2026-02-26T12:49:35.000Z - 2 months ago

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

2026-02-26T12:48:53.000Z - 2 months ago

Crescent Biopharma sees cash runway into 2028

Feb 26, 2026, 7:30 AM EST - 2 months ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 23, 2026, 7:30 AM EST - 2 months ago

Crescent Biopharma to Present at March Investor Conferences

2026-02-19T12:41:45.000Z - 2 months ago

Crescent Biopharma announces grants of inducement awards

2026-02-18T12:36:19.000Z - 3 months ago

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

Feb 18, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 12, 2026, 11:30 AM EST - 3 months ago

Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-28T11:36:53.000Z - 3 months ago

Crescent Biopharma initiated with an Overweight at Piper Sandler

2026-01-21T11:35:26.000Z - 4 months ago

Crescent Biopharma initiated with a Buy at Guggenheim

SMMT

2026-01-07T22:15:16.000Z - 4 months ago

Crescent Biopharma files to sell 19.71M shares of common stock for holders

2026-01-05T12:16:19.000Z - 4 months ago

Crescent Biopharma announces regulatory clearance of IND applications

Jan 5, 2026, 7:00 AM EST - 4 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

2025-12-04T20:35:38.000Z - 5 months ago

Crescent Biopharma price target raised to $32 from $28 at Stifel

2025-12-04T13:54:36.000Z - 5 months ago

Why Is Crescent Biopharma Stock (CBIO) Up Today?

Dec 4, 2025, 8:00 AM EST - 5 months ago

Crescent Biopharma Transcript: Partnership

Dec 4, 2025, 6:35 AM EST - 5 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:30 AM EST - 5 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Nov 19, 2025, 4:30 AM EST - 6 months ago

Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 6 months ago

Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 6 months ago

Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-06T12:43:44.000Z - 6 months ago

Crescent Biopharma reports Q3 EPS ($1.27), two est. ($1.38)

Nov 6, 2025, 7:30 AM EST - 6 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 5, 2025, 7:30 AM EST - 6 months ago

Crescent Biopharma to Present at November Investor Conferences

2025-11-04T14:16:54.000Z - 6 months ago

Crescent Biopharma to present preclinical data from CR-001

Nov 4, 2025, 9:05 AM EST - 6 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 8, 2025, 5:35 PM EDT - 8 months ago

Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 1:00 PM EDT - 8 months ago

Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:30 AM EDT - 9 months ago

Crescent Biopharma to Present at September Investor Conferences

2025-08-25T08:45:09.000Z - 9 months ago

Crescent Biopharma initiated with a Buy at Jefferies

Jul 31, 2025, 7:34 AM EDT - 10 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jun 16, 2025, 7:00 AM EDT - 11 months ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 5, 2025, 4:01 PM EDT - 1 year ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

May 29, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:55 PM EDT - 1 year ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Jul 25, 2024, 9:00 AM EDT - 1 year ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

Jun 4, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

May 29, 2024, 4:01 PM EDT - 2 years ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 20, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Sep 6, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 5, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 2, 2023, 7:00 AM EDT - 3 years ago

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

NVDAMillionaire May. 13 at 6:04 PM

0 · Reply

MorenitaScorp May. 5 at 2:18 PM

$CBIO ⌚️

0 · Reply

PenkeInvesting May. 4 at 4:20 PM

Fundamental analysis of $CBIO (CRESCENT BIOPHARMA, INC.) based on financial data and reported results. #CBIO

0 · Reply

OfficialStocktwitsUser May. 2 at 12:33 AM

0 · Reply

lyonsa14 May. 1 at 5:56 PM

$CBIO Looks like it’s falling in sympathy with Summit Therapeutics. https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble

0 · Reply

ProfProfit May. 1 at 3:44 PM

$CBIO why the 30% drop today?

0 · Reply

stockanalysis_ May. 1 at 1:49 PM

Losers Today: $CREG $SKBL $CBIO $SDOT $BAFN Download this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

SuperGreenToday Apr. 28 at 8:54 AM

$CBIO

0 · Reply

Estimize Apr. 21 at 11:03 PM

Wall St is expecting -0.88 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c

0 · Reply

Jt11111 Apr. 21 at 7:36 PM

$CBIO something gotta be cooking

0 · Reply

stocktrade77 Apr. 17 at 6:00 PM

$CBIO swing closed - banked , taken out most of it - just leaving rest for fun

0 · Reply

ProfProfit Apr. 17 at 5:10 PM

$CBIO why no attention on this thing? It’s green almost everyday for a month now and literally doubled its value in that time

0 · Reply

SSRbenny Apr. 17 at 3:45 AM

$CBIO anyone wanna tell me when the Markt cap became $500M????

0 · Reply

Jt11111 Apr. 14 at 7:33 PM

$CBIO liking this a lot!

0 · Reply

Stonski Apr. 7 at 8:51 PM

$QNCX can we stop with the space X NONSENSE GUYS 😭😭 .. this is gonna be $CBIO 2.0 it’s gonna be a biotech company that takes over the ticker As for why it’s mooning today my guess will be the clean up of the financials ( debt free rn) n talks are heating up

0 · Reply

lyonsa14 Apr. 1 at 11:01 PM

$CBIO Or, may be discussions regarding M&A. I suspect it’s either this or early data results are leaking out. This is just speculation.

0 · Reply

lyonsa14 Apr. 1 at 8:02 PM

$CBIO Just speculation, but likely insiders are seeing early data that looks promising. This is just a guess based on the rapid recent stock price increase. It’s more than obvious that it’s not a level playing field for small retail investors. Biotech investing is very difficult.

0 · Reply

SSRbenny Apr. 1 at 2:41 PM

$CBIO we had insiders loading up or what’s the deal here?

0 · Reply

DeepBlueTitan Mar. 31 at 1:37 AM

$CBIO on watch

0 · Reply

topstockalerts Mar. 30 at 6:00 PM

$CBIO this is the kind of action that builds confidence for buyers

0 · Reply

Wallstreetiscriminal Mar. 26 at 7:58 PM

$CBIO @ Billy Peters are you looking at the perceived increase that was actually the RS that took place several months back? I don’t recall a 500% increase just losses from a RS

0 · Reply

slick3333 Mar. 19 at 1:34 AM

$CBIO a bottomless pit coming to a stick near you

0 · Reply

Market Cap	510.36M
Revenue (ttm)	10.84M
Net Income (ttm)	-153.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,420.11%
Debt to Equity Ratio	0.00

Volume	251,815
Avg Vol	265,420
Day's Range	N/A - N/A
Shares Out	27.56M
Stochastic %K	43%
Beta	1.21
Analysts	Strong Sell
Price Target	$30.29